Storia in 3 fonti

Tata 1mg turns EBITDA positive across core businesses in FY26

Tata 1mg turned EBITDA positive across its core businesses in FY26 as diagnostics, ePharmacy and AI-led healthcare services expanded rapidly.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

yourstory.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo3 g fa

Tata 1mg turns EBITDA positive across core businesses in FY26

Tata 1mg turned EBITDA positive across its core businesses in FY26 as diagnostics, ePharmacy and AI-led healthcare services expanded rapidly.

originale

economictimes.indiatimes.com3 g fa

Tata 1mg turns Ebitda positive across core units as diagnostics crosses Rs 600 cr in ARR - The Economic Times

The company said its diagnostics business crossed an annualised revenue run rate of more than Rs 600 crore during the year, growing over 40 per cent year-on-year while sustaining double-digit Ebitda margins.

Leggi questa versione → originale

yourstory.com1 g fa

Tata 1mg turns EBITDA positive across core businesses

Tata 1mg achieved EBITDA positivity across all core business verticals in December 2025, with diagnostics crossing ₹600 crore ARR at 40%+ YoY growth and Specialty Pharma up 65% in FY26. For healthcare and digital health stack decisions, this signals that integrated omnichannel models—combining ePharmacy, diagnostics, and AI-driven platforms like its Pulse (used by 75+ pharma companies)—can reach sustainable unit economics at scale in emerging markets.

Leggi questa versione → originale

Timeline cronologica

mercoledì 27 maggio 2026·economictimes.indiatimes.com
Tata 1mg turns Ebitda positive across core units as diagnostics crosses Rs 600 cr in ARR - The Economic Times
The company said its diagnostics business crossed an annualised revenue run rate of more than Rs 600 crore during the year, growing over 40 per cent year-on-year while sustaining…
mercoledì 27 maggio 2026·thehindubusinessline.com
Tata 1mg turns EBITDA positive across core businesses in FY26
Tata 1mg turned EBITDA positive across its core businesses in FY26 as diagnostics, ePharmacy and AI-led healthcare services expanded rapidly.
venerdì 29 maggio 2026·yourstory.com
Tata 1mg turns EBITDA positive across core businesses
Tata 1mg said its approach of building integrated healthcare platform is delivering results and now planning an expansion of retail presence